Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.35 |
| ▸ | HTR2B | P41595 | 7/20 | 0.35 |
| ▸ | HTR2A | P28223 | 8/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | HRH2 | P25021 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740219 | 1.00 | HTR2C (0.35) | HTR2CHTR2BHTR2AHTR1AADRB2 | |
| SCHEMBL14766062 | 0.92 | HTR2C (0.36) | HTR2CHTR2BHTR2AHTR1AADRB2 | |
| SCHEMBL14766814 | 0.92 | HTR2C (0.36) | HTR2CHTR2BHTR2AHTR1AADRB2 | |
| SCHEMBL10302591 | 0.90 | HTR2C (0.35) | HTR2CHTR2BHTR2AHTR1AADRB2 | |
| SCHEMBL12736648 | 0.90 | HTR2C (0.33) | HTR2CHTR2BHTR2AHTR1AADRB2 | |
| SCHEMBL12736619 | 0.89 | KDM4E (0.33) | HTR1A | |
| SCHEMBL12736618 | 0.89 | KDM4E (0.31) | HTR1A | |
| SCHEMBL12740221 | 0.89 | KDM4E (0.33) | HTR1A | |
| SCHEMBL12740220 | 0.89 | KDM4E (0.31) | HTR1A | |
| SCHEMBL172389 | 0.89 | HTR2C (0.42) | HTR2CHTR2BHTR2AHTR1AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | HTR2C 253/4885HTR2B 932/4885HTR2A 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.